Healthcare
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companiesFOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Chinmaya Rath as Chief Business Officer. “Chinmaya is an experienced business development leader who will bring strategic insights and further executional
About this update from Geron Corporation
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Chinmaya Rath as Chief Business Officer. "Chinmaya is an experienced business development leader who will bring strategic insights and further executional focus to our team," said Harout Semerjian, President and Chief Executive Officer of Geron. "His appointment underscores our continued dedication to maximizing the value of RYTELO across the globe and evaluating opportunistic innovation to build a leading hematology company." "RYTELO's best-in-class profile, strong commercial performance in lower-risk myelodysplastic syndromes, along with the management team's commitment to operational excellence, position Geron well for continued growth," said Mr. Rath. "I am honored to join Geron at this exciting time in the company's evolution and look forward to working with the team to make a meaningful impact on the lives of people with blood cancers." Mr. Rath brings over 25 years of U.S. and global biopharma leadership experience to Geron. He spent a significant portion of his career at Novartis, advancing through roles of increasing responsibility with substantial experience leading high-impact, enterprise-wide strategic initiatives, including the integrations of GSK Oncology and Alcon. Most recently, he served as Head of Pharma Solutions at Cellworks and Chief Business Officer at GlycoMimetics. He also served as Founder CEO of CelluRx, and as Vice President of Innovation and Strategic Alliances at Omega Therapeutics. He has been instrumental in major U.S. launches across both hematology (Tasigna® TFR, Ped) and solid tumors (Lynparza® ovarian cancer, co-promotion with Merck). He formerly served as Head of Strategy and Operations for the Novartis U.S. Oncology Business Unit. Additionally, as a Venture Partner with Social Impact Capital, he represents the firm on the Board of Directors at Catena Biosciences and as a Board Observer at Menten AI. Mr. Rath received his MBAs from Warwick Business School in the United Kingdom and Army Institute of Management studies in India. He completed his undergraduate studies in Life Science with honors from Ravenshaw University, India. About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn .